论文部分内容阅读
[目的]观察XELOX方案联合消癌平注射液治疗进展期胃癌的疗效。[方法]56例进展期胃癌随机分为2组,治疗组(28例)接受消癌平注射液加XELOX方案(奥沙利铂+希罗达),对照组(28例)单用XELOX方案。2组均以3周为1个周期,至少完成2个周期,观察2组的疗效和不良反应。[结果]治疗组有效率为53.3%,对照组为43.8%,2组比较差异无统计学意义(P<0.05);治疗组临床受益率、生活质量KPS评分高于对照组(P<0.05)。治疗组III~IV度白细胞下降明显低于对照组,差异有统计学意义(P<0.05)。治疗组和对照组的中位无疾病进展生存时间(PFS)分别为167d和165d(P>0.05),治疗组和对照组的1年生存率分别为25.0%和21.4%(P<0.05)。[结论]XELOX方案联合消癌平注射液治疗进展期胃癌有较好疗效,改善患者的生活质量,III~IV度白细胞下降发生率低,值得临床推广使用。其远期疗效PFS、1年生存率等资料还需扩大样本进一步验证。
[Objective] To observe the curative effect of XELOX combined with Xiaochangping Injection in the treatment of advanced gastric cancer. [Method] 56 cases of advanced gastric cancer were randomly divided into 2 groups. The treatment group (28 cases) received XJOXX injection plus XELOX regimen (oxaliplatin + Xeloda) and the control group (28 cases) XELOX regimen alone . Two groups were 3 cycles for a cycle, at least completed 2 cycles, the efficacy and adverse reactions observed in two groups. [Results] The effective rate was 53.3% in the treatment group and 43.8% in the control group, with no significant difference between the two groups (P <0.05). The clinical benefit rate and quality of life KPS score of the treatment group were higher than those of the control group (P <0.05) . Treatment group III ~ IV leukopenia was significantly lower than the control group, the difference was statistically significant (P <0.05). The median progression-free survival time (PFS) was 167 days in the treatment group and 165 days in the control group (P> 0.05). The 1-year survival rates of the treatment group and the control group were 25.0% and 21.4%, respectively (P <0.05). [Conclusion] XELOX combined with Xiaojianping injection has a good curative effect on advanced gastric cancer and improves the quality of life of patients. The incidence of leukopenia in III-IV is low, which is worthy of clinical promotion. The long-term efficacy of PFS, 1-year survival rate and other data need to expand the sample for further verification.